



Lophos Holdings Inc. Announces Cure of Default and Progress Towards Financing

Vancouver, August 20, 2024 — Lophos Holdings Inc. (“Lophos” or the “Company”) (CSE:MESC), a Canadian biopharma company focused on the cultivation and sale of *Lophophora williamsii* (“Peyote”), is pleased to announce that the Company is no longer in default on its building interest payments. The default has been cured as of Friday, August 16, 2024.

This significant milestone reflects Lophos' continued commitment to maintaining strong financial health as we advance toward our strategic goals. With this matter resolved, the Company is now focused on securing the final stages of financing necessary to drive our operations forward into revenue generation and first sales.

Key Highlights:

- **Default Cured:** Lophos has successfully addressed and cured the default on its building interest payments.
- **Financing Progress:** We are in the final stages of securing the financing required to accelerate our entry into the market, which will pave the way for our first product sales.
- **Join Our Waiting List:** As we prepare to launch, we invite the public to join our waiting list for exclusive updates and priority access to our psychedelic products. Don't miss out on being among the first to experience our innovative offerings.

Claire Stawnyczy, CEO of Lophos, commented, "We are thrilled to have resolved the default on our building interest payments and are excited about the progress we are making towards securing the necessary financing to drive our sales forward. We appreciate the ongoing support of our stakeholders and look forward to achieving new milestones in the near future."

To join our waiting list and stay informed about our upcoming product launches, please visit www.lophos.com or contact us at info@lophos.com.

About Lophos Holdings Inc.

Lophos Holdings Inc. (CSE:MESC), is a holdings company focused in the bioscience sector. Lophos Pharmaceuticals Corp., a wholly owned subsidiary of Lophos Holdings Inc., stands as a prominent biosciences company specializing in the cultivation, research, and sale of peyote. Distinguished by its Controlled Substances Dealers License (CSDL), the subsidiary is authorized for the possession, sale, sending, transportation, and delivery of various controlled substances, including

mescaline, psilocin, psilocybin, LSD, DMT, MDMA, and ketamine. Additionally, the license grants permission for the production of mescaline, psilocin, and psilocybin, showcasing the comprehensive scope of their operations.

For Further Inquiries

Contact: Claire Stawnyczy – CEO, Lophos Holdings Inc.

Email: invest@lophos.com

Website: www.lophos.com

Phone: 1-833-450-7407

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Cautionary Statement

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lophos' current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company's peyote cactus product development. Forward-looking information is based on reasonable assumptions that have been made by Lophos at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Lophos is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Lophos' final long form prospectus dated August 11, 2023, which is available on Lophos's profile at www.sedarplus.ca.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in

which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

###